Ovid Therapeutics (OVID) Cash from Operations Growth (1y) (2017 - 2026)
Ovid Therapeutics (OVID) Cash from Operations Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ovid Therapeutics | 118.66 Mn | -36.86 Mn | - | -35.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.20% |
| Dec 31, 2025 | -3.66% |
| Sep 30, 2025 | 14.53% |
| Jun 30, 2025 | 66.19% |
| Mar 31, 2025 | 38.39% |
| Dec 31, 2024 | 15.98% |
| Sep 30, 2024 | -49.29% |
| Jun 30, 2024 | -21.78% |
| Mar 31, 2024 | -37.76% |
| Dec 31, 2023 | -29.81% |
| Sep 30, 2023 | 20.70% |
| Jun 30, 2023 | 11.91% |
| Mar 31, 2023 | 39.70% |
| Dec 31, 2022 | 23.53% |
| Sep 30, 2022 | -16.60% |
| Jun 30, 2022 | 31.56% |
| Mar 31, 2022 | -112.48% |
| Dec 31, 2021 | 17.31% |
| Sep 30, 2021 | -639.88% |
| Jun 30, 2021 | -12.93% |